PATENT APPLICATION
DOCKET NO.: 2478.2017-001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Approant:

John M. Williams

Application No.:

10/719,701

Group Art Unit:

1646

Filed:

November 21, 2003

Examiner:

Not Assigned

Confirmation No.:

1350

Title:

Induction of Immune Tolerance

CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on: The pate Carol M. Bowerman

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-145

Alexand	dria, VA 22313-1450
Sir:	
This In	iformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statem	ent Unde	r 37 CFR 1.97(e)
[]	Each ite	m of information contained in this Information Disclosure Statement was first elect in munication from a foreign patent office in a counterpart foreign application not more months prior to the filing of this Information Disclosure Statement; or
[]	No item	of information contained in this Information Disclosure Statement was cited in a nication from a foreign patent office in a counterpart foreign application, and, to the nication from a foreign patent office in a counterpart foreign application, and, to the nication from a foreign patent office in a counterpart foreign application, and, to the dge of the undersigned, after making reasonable inquiry, no item of information contained after making reasonable inquiry, no item of information contained in 37 CFR information disclosure statement was known to any individual designated in 37 CFR more than three months prior to the filing of this Information Disclosure Statement.
State	ment Und	ler 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	commi	em of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication at received by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.
U		
[X]	Enclos	sed herewith is form PTO-1449:
	[X]	Copies of the cited references are enclosed.
	[<u>3</u>	[X] Since this application was filed after June 30, 2003, copies of issued 0.5. patents and published U.S. applications are not required and are not being provided.
	[]	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier Application copies of the cited references.]
	[X]	The listed references, AL, AM, AN, AS and AT, were cited in the enclosed International Search Reports in counterpart foreign applications.
	[]	The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
		[] the explanation provided on the attached sheet.
		[] the explanation provided in the Specification.
		[] submission of the enclosed International Search Report.
·		submission of the enclosed international control of a foreign Search Report submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
*		[] the enclosed English language abstract.

[X] Applicant requests that the following no	on-published pending applications be considered:
	/719,055, by John M. Williams, filed November 21, 2003,], by [inventor(s)], filed [], Docket No.: []], by [inventor(s)], filed [], Docket No.: []
A copy of each above-cited a those entered in prior application 35 U.S.C. 120 is claimed.	application, including the current claims, is enclosed. application, including the current claims, is enclosed, except ation, U.S. Application No. [], to which priority under of the above list of pending applications indicating which affice communication. The description of the current claims, is enclosed.
Method of payment: [] A check for the fee noted above is accompanying Reply. A copy of	s enclosed, or the fee has been included in the check with the this Statement is enclosed.

Concord, MA 01742-9133 Dated: 1 8, 2004 PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 2, 2004

July 2, 2004

July 2, 2004

ATTORNEY DOCKET NO.

2478.2017-001

FIRST NAMED INVENTOR
John M. Williams

APPLICATION NO.

10/719,701

FILING DATE
November

November 21, 2003

EXAMINER
Not Assigned

CONFIRMATION NO. GROUP 1350 1646

	U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
	AA	5,540,931	07-30-1996	Hewitt, et al.		
	AB	5,654,312	08-05-1997	Andrulis, Jr., et al.		
	AC	5,795,967	08-18-1998	Aggarwal, et al.		
	AD	5,801,193	09-01-1998	Ojo-Amaize, et al.		
	AE	5,958,413	09-28-1999	Anagnostopulos, et al.		
	AF	5,990,103	11-23-1999	Schonharting, et al.		
•	AG	6,020,323	02-01-2000	Cohen, et al.		
	AH	6,030,615	02-29-2000	Bucala, et al.		
	AI	6,204,245	03-20-2001	Siegel, et al.		
	AJ	6,211,160	04-03-2001	Wilson, et al.		
	AK	6,235,281	05-22-2001	Stenzel, et al.		
	AA2	6,294,170	09-25-2001	Boone, et al.		
	AB2	6,270,766 B1	08-07-2001	Feldman, et al.		
	AC2	6,299,878	10-09-2001	Pierpadi, et al.		
	AD2	6,306,820 B1	10-23-2001	Bendele, et al.		
	AE2	6,331,560	12-18-2001	Shohami, et al.		
	AF2	6,337,325	01-08-2002	Schonharting, et al.		
	AG2	6,376,665	04-23-2002	Duan, et al.		
	AH2	6,420,374 B1	07-16-2002	Bianco, et al.		
	AI2	6,432,962	08-13-2002	Horneman		
	AJ2	6,432,968 B1	08-13-2002	Schonharting, et al.		
	AK2	6,503,184	01-07-2003	Ni, et al.		
	AA3	6,506,569 B1	01-14-2003	Ni, et al.		
	AB3	6,509,015 B1	01-21-2003	Salfeld, et al.		
	AC3	2002/0119988 A1	08-29-2002	Sneddon, et al.		

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED			PLICATION NO. /719,701		
INTERMATION DISCLOSURE CITATION IN AN APPLICATION			FILING DATE November		
JUL 1 2 2004 G July 2, 2004 Use several sheets if necessary)	EXAMINER Not Assigned	CONF	IRMATION NO.	GROUP 1646	
A MADDIARY					

	FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	ATION NO
	AL	WO 01/87849	11-22-2001	Genzyme Corporation		
	AM	WO 98/39026	09-11-1998	Biogen Inc.		
	AN	EP 0 401 747 A	12-12-1990	Calne		
	AO	WO 95/09652	04-13-1995	The Kennedy Institute for Rheumatology		
٤	AP	WO 94/08619	04-28-1994	The Kennedy Institute for Rheumatology		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	Yuan, X. et al., "A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection," <i>Transplantation</i> 73(11):1736-1742 (2002).				
AS	Turner, D. M., et al., "A Genetic Marker of High TNF-α Production in Heart Transplant Recipients," Transplantation, 60(10):1113-1117 (1995).				
AT	Couriel, D., et al., "TNF-Alpha Inhibition for the Treatment of Chronic GVHD," Blood, 100(11):847a (2002) Abstract.				
AU	Hancock, W. W., et al., "Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection," <i>Proc. Natl. Acad. Sci. USA 93</i> :13967-13972 (1996).				

EXAMINER	DATE CONSIDERED